United Therapeutics Corp

United Therapeutics Corp is a leading biotechnology company that specializes in developing and commercializing innovative therapies for patients suffering from chronic and life-threatening diseases. With a primary focus on pulmonary arterial hypertension (PAH), a rare and progressive disease that affects the lungs and heart, the company has successfully developed several FDA-approved treatments, including Remodulin, Tyvaso, and Orenitram. In addition to its current portfolio, United Therapeutics Corp has a robust pipeline of potential therapies for PAH, cancer, and organ transplantation. The company is dedicated to improving patient outcomes through scientific innovation and collaboration with healthcare professionals, patient advocacy groups, and other stakeholders. Headquartered in Silver Spring, Maryland, United Therapeutics Corp operates globally, with a presence in the United States, Europe, and Asia.